ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.95855
-0.08%
Brent Oil
83.54
-0.11%
Bitcoin
59,412.07
0.49%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Akero Therapeutics Inc (AKRO)

  7. Akero Therapeutics Inc (AKRO) Noticias

AKRO Akero Therapeutics Inc

19.71
0.00 (0.00%)
Pre Mercado
Última actualización: 03:01:28
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Akero Therapeutics Inc AKRO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 19.71 03:01:28
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
19.71
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202407:00GLOBEAkero Therapeutics Appoints Scott Gangloff as Chief..
08/3/202415:02GLOBEAkero Therapeutics Announces Closing of Public Offering of..
07/3/202415:01GLOBEAkero Therapeutics Announces Publication of Phase 2b..
06/3/202419:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202419:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202416:25EDGAR2Form 8-K - Current report
06/3/202416:16EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/3/202420:13GLOBEAkero Therapeutics Announces Pricing of Public Offering of..
05/3/202416:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202405:05IHMARKETNEWSAMD Hits Regulatory Roadblock, GitLab’s Stock Tumbles on..
04/3/202416:34EDGAR2Form 144 - Report of proposed sale of securities
04/3/202416:30EDGAR2Form 144 - Report of proposed sale of securities
04/3/202416:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202415:21GLOBEAkero Therapeutics Announces Proposed Public Offering of..
04/3/202406:55EDGAR2Form 8-K - Current report
04/3/202405:00GLOBEAkero Therapeutics Reports Statistically Significant..
29/2/202415:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202407:00GLOBEAkero Therapeutics to Present Topline Week 96 Results from..
29/2/202406:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202406:15EDGAR2Form 8-K - Current report
29/2/202406:00GLOBEAkero Therapeutics Reports Fourth Quarter and Full Year 2023..
13/2/202420:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
03/1/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202407:15GLOBEAkero Therapeutics to Present at the 42nd Annual J.P. Morgan..
29/12/202319:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202317:07EDGAR2Form 144 - Report of proposed sale of securities
18/12/202319:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202319:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202319:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202319:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202319:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202306:08EDGAR2Form 8-K - Current report
18/12/202306:00GLOBEAkero Therapeutics Announces First Patients Dosed in..
12/12/202315:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202320:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202319:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202307:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202316:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202306:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202306:15EDGAR2Form 8-K - Current report
13/11/202306:00GLOBEAkero Therapeutics Reports Third Quarter 2023 Financial..
10/11/202307:57GLOBEAkero Therapeutics to Present Late-Breaking Oral and Poster..
08/11/202306:00GLOBEAkero Therapeutics to Present at Upcoming Healthcare..
17/10/202315:05GLOBEAkero Therapeutics to Present at the H.C. Wainwright 7th..
10/10/202307:04EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
AKRO
Akero Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados